BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 16, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/13 cls
Biogen Idec Inc. (NASDAQ:BIIB) Stifel Nicolaus Weisel Joel Sendek Price target Buy 2% $144.61
Sendek raised his target to $167 from $144 on continued weakness for competing multiple sclerosis drug Gilenya fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN), which he believes increases the market potential for Biogen Idec's MS candidate BG-12. In April, both EMA and...

Read the full 483 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >